On the recordApril 4, 2022
Key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to support approval of innovative medicines for rare diseases.
Source
congress.govBob Casey: “Key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to…”
Editor's note · Context
Emphasizes the need for regulatory agreement on efficacy endpoints for rare disease drug approvals.
Share
More from Bob Casey
Aug 7, 2024
Thank you, Senator Casey, for organizing this hearing and for all you do to improve support for caregivers.
Sep 12, 2024
I am disappointed that Dr. de la Torre defied the subpoena this Committee authorized and has chosen not to appear today.
Other voices in this conversation
